Preclinical Model to Evaluate Outcomes of Amyloid Cross-Toxicity in the Rodent Brain

ACS Chem Neurosci. 2022 Oct 19;13(20):2962-2973. doi: 10.1021/acschemneuro.2c00419. Epub 2022 Oct 4.

Abstract

The progress of neurodegenerative disorders correlates with the spread of their associated amyloidogenic proteins. Here, we investigated whether amyloid entry into nonconstitutive neurons could drive cross-toxic outcomes. Amyloid β (Aβ) was stereotaxically introduced into the rodent midbrain tegmentum, where it is not endogenously expressed. Postinfusion, rodent motor and sensorimotor capacities were assessed by standard behavioral tests at 3, 6, 9, and 12 months. The longitudinal study revealed no behavioral abnormalities. However, Aβ insult provoked intraneuronal inclusions positive for phosphorylated α-synuclein in dopaminergic neurons and were seen throughout the midbrain, a pathognomonic biomarker suggesting Parkinson's pathogenesis. These findings not only underscore the cross-toxic potential of amyloid proteins but also provide a mechanism by which they disrupt homeostasis in nonconstitutive neurons and cause neuronal corruption, injury, and demise. This study may help reconcile the large incidence of neurodegenerative comorbidity observed clinically.

Keywords: Alzheimer’s disease; Parkinson’s disease; amyloid infiltration; amyloid-β; cross-pathology; cross-seeding; cross-toxicity; phosphorylated α-synuclein; protein colocalization; synucleinopathies; toxic oligomeric proteins.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Amyloid / metabolism
  • Amyloid beta-Peptides / metabolism
  • Amyloid beta-Peptides / toxicity
  • Amyloidogenic Proteins / metabolism
  • Amyloidosis* / metabolism
  • Animals
  • Biomarkers / metabolism
  • Brain / metabolism
  • Dopaminergic Neurons / metabolism
  • Longitudinal Studies
  • Rodentia / metabolism
  • alpha-Synuclein* / metabolism

Substances

  • alpha-Synuclein
  • Amyloid beta-Peptides
  • Amyloid
  • Amyloidogenic Proteins
  • Biomarkers